Table 1. MSP positivity in the external validation cohort of FFPE tissue samples.
Gene | Normal | Cancer | ADC | SCC | ||||
---|---|---|---|---|---|---|---|---|
TBX5 | 56% | (9/16) | 67% | (8/12) | 60% | (3/5) | 71% | (5/7) |
SOX14* | 25% | (4/16) | 85% | (11/13) | 83% | (5/6) | 86% | (6/7) |
SOX1* | 0% | (0/15) | 92% | (11/12) | 100% | (5/5) | 86% | (6/7) |
TBX20* | 6% | (1/17) | 83% | (10/12) | 100% | (5/5) | 71% | (5/7) |
SLC6A5* | 7% | (1/15) | 83% | (10/12) | 100% | (5/5) | 71% | (5/7) |
GFRA1* | 0% | (0/11) | 83% | (10/12) | 83% | (5/6) | 83% | (5/6) |
the positive rates in normal and cancer samples differ (P < 0.05).